ADVANCES IN NONINVASIVE DRUG DELIVERY SYSTEMS OF OPIOIDS: FORMULATIONS AND CLINICAL PERSPECTIVE

Authors

  • Dhanashree A Mundhey
  • Nidhi P Sapkal
  • Anwar S Daud

Abstract

ABSTRACT
Opioid continues as the main pharmacological treatment for severe acute pain. Extensive first-pass metabolism is the major limitation of opioid
delivery by oral route. Thus, the parenteral route has been the only option for the delivery of opioids before the beginning of the 21
century.
However, as the delivery through parenteral route is associated with limitation of being invasive, a strong need for developing non-invasive delivery
systems has been felt among the drug delivery scientists. Since mucosal surfaces are rich in blood supply and provide rapid drug transport to the
systemic circulation, this delivery system has been explored to enhance opioid bioavailability by avoiding their degradation through first-pass hepatic
metabolism. Oral transmucosal delivery such as buccal and sublingual has progressed far beyond the use of traditional dosage forms developed with
novel approaches emerging continuously. This review provides updated information about the use of opioids for the treatment of severe pain with
special emphasis on the work done by various scientists on formulation development of opioid analgesics, especially by buccal and sublingual route
for delivery of opioids along with their clinical perspective. Particular attention is given to new approaches enhancing bioavailability of opioids by
these routes.
Keywords: Opioids, Buccal, Oral drug, Sublingual delivery of opioids.
st

Downloads

Download data is not yet available.

References

REFERENCES

Nersesyan H, Slavin KV. Current approach to cancer pain management:

Availability and implications of different treatment options. Ther Clin

Risk Manag 2007;3(3):381-400.

Rang HP, Dale MM, Ritter JM. Rang & Dale’s Pharmacology. 6

ed.

Edinburg: Churchill Livingstone; 2007.

Stevens RA, Ghazi SM. Routes of opioid analgesic therapy in the

management of cancer pain. Cancer Control 2000;7(2):132-41.

Morales ME, Gallardo Lara V, Calpena AC, Doménech J, Ruiz MA.

Comparative study of morphine diffusion from sustained release

polymeric suspensions. J Control Release 2004;95(1):75-81.

Koocheki S, Madaeni SS, Niroomandi P. Development of an enhanced

formulation for delivering sustained release of buprenorphine

hydrochloride. Saudi Pharm J 2011;19(4):255-62.

Zamloot M, Chao W, Kang LL, Ross J, Fu R. Remoxy

: A novel

formulation of extended release oxycodone developed using the

Oradur

technology. J Appl Res 2010;10(3):88-96.

Friedmann N, Klutzaritz V, Webster L. Long-term safety of Remoxy®

®

(extended-release oxycodone) in patients with moderate to severe

chronic osteoarthritis or low back pain. Pain Med 2011;12(5):755-60.

Senel S, Kremer M, Nagy K, Squier C. Delivery of bioactive peptides

and proteins across oral (buccal) mucosa. Curr Pharm Biotechnol

;2(2):175-86.

®

th

Asian J Pharm Clin Res, Vol 9, Issue 4, 2016, 341-347

Mundhey et al.

Lalla JK, Gurnacy RA. Polymers for mucosal delivery swelling and

mucoadhesive evaluation. Indian Drugs 2002;39(5):270-6.

Sattar M, Sayed OM, Lane ME. Oral transmucosal drug delivery –

Current status and future prospects. Int J Pharm 2014;471(1-2):498-506.

Anlar S, Capan Y, Güven O, Gögüs A, Dalkara T, Hincal AA.

Formulation and in vitro-in vivo evaluation of buccoadhesive morphine

sulfate tablets. Pharm Res 1994;11(2):231-6.

Aiache JM. Process for preparing a bioadhesive pharmaceutical dosage

form and pharmaceutical dosage form thus prepared. U.S. Patent

,362,498 November 8, 1994.

Beyssac E, Touaref F, Meyer M, Jacob L, Sandouk P, Aiache JM.

Bioavailability of morphine after administration of a new bioadhesive

buccal tablet. Biopharm Drug Dispos 1998;19(6):401-5.

Gordon DB. New opioid formulations and delivery systems. Am Soc

Pain Manag Nurs 2007;8(3):S6-13.

Kim KS, Simon L. Transport mechanisms in oral transmucosal

drug delivery: Implications for pain management. Math Biosci

;229(1):93-100.

Rathbone M, Senel S, Pather I. Oral Mucosal Drug Delivery and

Therapy. 1

ed. New York, Heidelberg, London: Springer; 2015.

Comerford D. Techniques of opioid administration. Anaesth Intensive

st

Care Med 2008;9(1):21-6.

Schechter NL, Weisman SJ, Rosenblum M, Bernstein B, Conard PL.

The use of oral transmucosal fentanyl citrate for painful procedures in

children. Pediatrics 1995;95(3):335-9.

Highlights of Prescribing Information. FENTORA

Fentanyl Citrate

Buccal Tablet. Available from: http://www.accessdata.fda.gov/

drugsatfda_docs/label/2011/021947s013lbl.pdf.

®

Darwish M, Kirby M, Robertson P Jr, Tracewell W, Jiang JG.

Pharmacokinetic properties of fentanyl effervescent buccal tablets: A

phase I, open-label, crossover study of single-dose 100, 200, 400, and

microg in healthy adult volunteers. Clin Ther 2006;28(5):707-14.

Manco L, Messina J, Portenoy R. A randomized, placebo controlled

study of fentanyl effervescent buccal tablets for breakthrough pain in

opioid tolerant patients with cancer. Poster Presented at 22

Annual

Meeting of American Academy of Pain Medicine 2006; Manchester, San

Diego. Available from: https://www.aapm.confex.com/aapm/2006am/

techprogram/P1161.HTM.

Kosugi T, Hamada S, Takigawa C, Shinozaki K, Kunikane H, Goto F,

et al. A randomized, double-blind, placebo-controlled study of fentanyl

buccal tablets for breakthrough pain: Efficacy and safety in Japanese

cancer patients. J Pain Symptom Manage 2014;47(6):990-1000.

Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the

relief of breakthrough pain in opioid tolerant adult patients with chronic

neuropathic pain: A multicentre, randomized, double blind, placebo

controlled study. Clin Ther 2007;29(4):588-601.

Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral

fentanyl formulations vs. oral morphine for cancer-related breakthrough

pain: A meta-analysis of comparative trials. J Pain Symptom Manage

;46(4):573-80.

Fine PG, Messina J, Xie F, Rathmell J. Long-term safety and tolerability

of fentanyl buccal tablet for the treatment of breakthrough pain in

opioid-tolerant patients with chronic pain: An 18-month study. J Pain

Symptom Manage 2010;40(5):747-60.

Hearnden V, Sankar V, Hull K, Juras DV, Greenberg M, Kerr AR, et al.

New developments and opportunities in oral mucosal drug delivery for

local and systemic disease. Adv Drug Deliv Rev 2012;64(1):16-28.

Tapolsky GH, Osborne DW. Bioerodable film for delivery of

pharmaceutical compounds of mucosal surface. U.S. Patent

,159,498 December 12, 2000.

Tapolsky GH, Osborne DW. Pharmaceutical carrier device suitable for

delivery of pharmaceutical compounds to mucosal surface. U.S. Patent

,579,019 August 25, 2009.

Gordon DB. Oral transmucosal fentanyl citrate for cancer breakthrough

pain: A review. Oncol Nurs Forum 2006;33(2):257-64.

Diaz del Consuelo I, Falson F, Guy RH, Jacques Y. Ex vivo evaluation

of bioadhesive films for buccal delivery of fentanyl. J Control Release

;122(2):135-40.

Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal

soluble film (FBSF) for breakthrough pain in patients with cancer:

A randomized, double-blind, placebo-controlled study. Ann Oncol

;21(6):1308-14.

Finn A, Vasisht N. Transmucosal delivery devices with enhanced

uptake. U.S. Patent 8,147,866 April 3, 2012.

Abuse-resistant mucoadhesive devices for delivery of buprenorphine.

U.S. Patent 8,703,177 April 22, 2014.

Bai SA, Xiang Q, Finn A. Evaluation of the pharmacokinetics of

nd

single - And multiple-dose buprenorphine buccal film in healthy

volunteers. Clin Ther 2016;38(28):358-69.

Sullivan JG, Webster L. Novel buccal film formulation of buprenorphinenaloxone

for

the maintenance treatment

of

opioid dependence:

A

-Week

conversion study.

Clin Ther

;37(5):1064-75.

Guo JH. Bioadhesive polymer buccal patches for buprenorphine

controlled delivery: Formulation, In vitro adhesion and release

properties. Drug Dev Ind Pharm 1994;20(18):2809-21.

Han RY, Fang JY, Sung KC, Hu OY. Mucoadhesive buccal disks for

novel nalbuphine prodrug controlled delivery: Effect of formulation

variables on drug release and mucoadhesive performance. Int J Pharm

;177(2):201-9.

Parodi B, Russo E, Caviglioli G, Vallarino M, Fusco F, Henriquet F.

Buccoadhesive oxycodone hydrochloride disks: Plasma

pharmacokinetics in healthy volunteers and clinical study. Eur J Pharm

Biopharm 1997;44(2):137-42.

Patel VF, Liu F, Brown MB. Advances in oral transmucosal drug

delivery. J Control Release 2011;153(2):106-16.

Ciach T, Moscicka-Studzinska A. Buccal iontophoresis: An opportunity

for drug delivery and metabolite monitoring. Drug Discov Today

;16(7-8):361-6.

Streisand JB, Stanley TH. Newer drug delivery systems. Curr Anaesth

Crit Care 1995;6(2):113-20.

Campisi G, Giannola LI, Florena AM, De Caro V, Schumacher A,

Göttsche T, et al. Bioavailability in vivo of naltrexone following

transbuccal administration by an electronically-controlled intraoral

device: A trial on pigs. J Control Release 2010;145(3):214-20.

Giannola LI, De Caro V, Giandalia G, Siragusa MG, Tripodo C,

Florena AM, et al. Release of naltrexone on buccal mucosa: Permeation

studies, histological aspects and matrix system design. Eur J Pharm

Biopharm 2007;67(2):425-33.

Walton RP. Absorption of drugs through the oral mucosa: III. Fatwater

solubility coefficient

of

alkaloids.

Proc Soc Exp Bio Med

;32(9):1488-92.

Weinberg DS, Inturrisi CE, Reidenberg B, Moulin DE, Nip TJ,

Wallenstein S, et al. Sublingual absorption of selected opioid analgesics.

Clin Pharmacol Ther 1988;44(3):335-42.

Fudala PJ, Johnson RE. Development of opioid formulations

with limited diversion and abuse potential. Drug Alcohol Depend

;83 Suppl 1:S40-7.

Orange Book: Approved Drug Products with Therapeutic Equivalence

Evaluations. U.S. Food & Drug Administration.

Lewis JW, Lloyd JG. Analysis compositions. U.S. Patent 4,582,835 April

, 1986.

Pettersson A, Nystrom C. Pharmaceutical composition for the treatment

of acute disorder. U.S. Patent 8,454,996 B2 June 4, 2013.

Pettersson A. Non-abusable pharmaceutical composition comprising

opioids. U.S. Patent 8,470,361 B2 June 25, 2013.

Pettersson A. Non-abusable pharmaceutical composition comprising

opioids. U.S. Patent 8,658,198 B2 February 25, 2014.

Fischer A. Abuse resistant pharmaceutical composition for the treatment

of opioid dependence. U.S. Patent 8,940,330 B2 January 27, 2015.

Fischer A. Abuse resistant pharmaceutical composition for the treatment

of opioid dependence. U.S. Patent 9,259,421 B2 February 16, 2016.

Fischer A, Jönsson M, Hjelmström P. Pharmaceutical and

pharmacokinetic characterization of a novel sublingual buprenorphine/

naloxone tablet formulation in healthy volunteers. Drug Dev Ind Pharm

;41(1):79-84.

Bredenberg S, Duberg M, Lennernäs B, Lennernäs H, Pettersson A,

Westerberg M, et al. In vitro and in vivo evaluation of a new sublingual

tablet system for rapid oromucosal absorption using fentanyl citrate as

the active substance. Eur J Pharm Sci 2003;20(3):327-34.

Myers GL, Fuisz JM. Sublingual and buccal film compositions. U.S.

Patent 8,475,832 July 2, 2013.

Yang RK, Fuisz RC, Myers GL, Fuisz JM. Polyethylene oxidebased

films

and drug

delivery systems

made therefrom.

U.S.

Patent

,017,150

September

, 2011.

Yang RK, Fuisz RC, Myers GL, Fuisz JM. Uniform films for rapid

dissolve dosage form incorporating taste-masking compositions. U.S.

Patent 8,603,514 December 10, 2013.

Yeola GS, Darandale S, Khire A, Vavia PR. Fabrication and statistical

optimization of a polysaccharide-based sublingual film of buprenorphine

hydrochloride for breakthrough pain management: In vitro and in vivo

performance. Drug Deliv Transl Res 2014;4(2):116-25.

Soyka M. Buprenorphine-naloxone buccal soluble film for the

treatment of opioid dependence: Current update. Expert Opin Drug

Deliv 2015;12(2):339-47.

Asian J Pharm Clin Res, Vol 9, Issue 4, 2016, 341-347

Mundhey et al.

Ling W, Mooney L, Zhao M, Nielsen S, Torrington M, Miotto K.

Selective review and commentary on emerging pharmacotherapies for

opioid addiction. Subst Abuse Rehabil 2011;2:181-8.

Lintzeris N, Leung SY, Dunlop AJ, Larance B, White N, Rivas GR,

et al. A randomised controlled trial of sublingual buprenorphinenaloxone

film

versus

tablets in

the management

of

opioid dependence.

Drug

Alcohol

Depend 2013;131(1-2):119-26.

Lavonas EJ, Banner W, Bradt P, Bucher-Bartelson B, Brown KR,

Rajan P, et al. Root causes, clinical effects, and outcomes of

unintentional exposures to buprenorphine by young children. J Pediatr

;163(5):1377-83.e1-3.

Boyer EW, McCance-Katz EF, Marcus S. Methadone and buprenorphine

toxicity in children. Am J Addict 2010;19(1):89-95.

Buprenorphine prescribing practices and exposures reported to a

poison center – Utah, 2002-2011. MMWR Morb Mortal Wkly Rep

;61:997-1001.

Kottayil SG, Goskonda VR, Zhu Z, Parikh N, Kattookaran L. Sublingual

Fentanyl Spray. U.S. Patent 8,486,972 B2 July 16, 2013.

Kottayil SG, Goskonda VR, Zhu Z, Parikh N, Kattookaran L. Sublingual

fentanyl spray. U.S. Patent 8,486,973 B2 July 16, 2013.

Kottayil SG, Goskonda VR, Zhu Z, Parikh N, Kattookaran L. Sublingual

fentanyl spray. U.S. Patent 8,835,459 B2 September 16, 2014.

Parikh N, Goskonda V, Chavan A, Dillaha L. Single-dose

pharmacokinetics of fentanyl sublingual spray and oral transmucosal

fentanyl citrate in healthy volunteers: A randomized crossover study.

Clin Ther 2013;35(3):236-43.

Palmer PP, Royal MA, Miller RD. Novel delivery systems

for postoperative analgesia. Best Pract Res Clin Anaesthesiol

;28(1):81-90.

Griffin DW, Skowronski RJ, Dasu BN, Palmer PP. A phase 2 openlabel

functionality,

safety,

and efficacy

study of the sufentanil

NanoTab

PCA system in patients following elective unilateral

knee replacement surgery. In: Poster Presented at the 35

TM

Annual

Spring Meeting and Workshops of the American Society of Regional

Anesthesia and Pain Medicine; April 22-25. Toronto, Ontario,

Canada; 2010.

Minkowitz HS, Singla NK, Evashenk MA, Hwang SS, Chiang YK,

Hamel LG, et al. Pharmacokinetics of sublingual sufentanil tablets

and efficacy and safety in the management of postoperative pain. Reg

Anesth Pain Med 2013;38(2):131-9.

RxList The Internet Drug Index. Available from: http://www.rxlist.

com/script/main/hp.asp.

U.S. National Library of Medicine. Available from: http://www.

Dailymed.nlm.nih.gov/dailymed/index.cfm.

RxList The Internet Drug Index. DILAUDID

(hydromorphone

hydrochloride) 8 mg Tablets. Available from: http://www.rxlist.com/

dilaudid-drug/clinical-pharmacology.htm.

®

U.S. National Library of Medicine. Dailymed. OXYCONTIN –

Oxycodone Hydrochloride Tablet, Film Coated, Extended. Available

from: http://www.dailymed.nlm.nih.gov/dailymed/drugInfo.

cfm?setid= bfdfe235-d717-4855-a3c8-a13d26dadede.

U.S. National Library of Medicine. Dailymed. Oxycodone

Hydrochloride – OXYCODONE Hydrochloride Capsule. Available

from: http://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?

th

setid=566ef 74d-5c0b-49bf-9619-e757d16431ef.

Pather IS, Khankari RK, Eichman JD, Robinson JR, Hontz J. Sublingual

buccal effervescent. U.S. Patent 6,200,604 March 13, 2001.

U.S. National Library of Medicine. Dailymed. FENTORA –

Fentanyl Citrate Tablet. Available from: http://www.dailymed.nlm.

nih.gov/dailymed/drugInfo.cfm?setid=8f549d95-985b-f783-1ebbef57bd2ecb05.

U.S. National Library of Medicine. Dailymed. LAZANDA –

Fentanyl Citrate Spray. Available from: http://www.dailymed.nlm.

nih.gov/dailymed/drugInfo.cfm?setid=9dcaff31-1653-11e3-8ffd0800200c9a66.

Transmucosal Immediate Release Fentanyl (TIRF) Risk Evaluation

and Mitigation Strategy (REMS) ACCESS. Onsolis - Fentanyl buccal

soluble film. Available from: https://www.tirfremsaccess.com/TirfUI/

rems/pdf/onsolis-prescribing-information.pdf.

U.S. National Library of Medicine. Dailymed. DURAGESIC – Fentanyl

Patch. Available from: http://www.dailymed.nlm.nih.gov/dailymed/

drugInfo.cfm?setid=d7aade83-9e69-4cd5-8dab-dbf1d7b89bb4.

Pettersson A, et al. Fentanyl composition for the treatment of acute

pain. U.S. Patent 6,759,059 July 6, 2004.

U.S. National Library of Medicine. Dailymed. ABSTRAL –

Fentanyl Citrate Tablet. Available from: http://www.dailymed.nlm.

nih.gov/dailymed/drugInfo.cfm?setid=f969e2bc-6297-4e29-89d3a3685a2c7c6b.

George Kottayil S, Long Grove IL. Sublingual Fentanyl Spray. U.S.

Patent 8,486,972 July 16, 2013.

George Kottayil S, Long Grove IL. Sublingual fentanyl spray. U.S.

Patent 8,486,973 July 16, 2013.

George Kottayil S, Long Grove IL. Sublingual fentanyl spray. U.S.

Patent 8,835,459 September 16, 2014.

George Kottayil S, Long Grove IL Sublingual fentanyl spray and

methods of treating pain. U.S. Patent 8,835,460 September 16, 2014.

U.S. National Library of Medicine. Dailymed. SUBSYS – Fentanyl

Spray. Available from: http://www.dailymed.nlm.nih.gov/dailymed/

drugInfo.cfm?setid=18a413e9-11e0-4a8f-86c0-d33b37b7b771.

U.S. National Librar$y of Medicine. Dailymed. BUPRENORPHINE

HCL – Buprenorphine Hydrochloride Tablet. Available from: http://

www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm ?setid=1bf8b35ab769-465c-a2f8-099868dfcd2f.

U.S. National Library of medicine. Dailymed. BUNAVAIL –

Buprenorphine hydrochloride and naloxone hydrochloride dehydrate

film. Available from: http://www.dailymed.nlm.nih.gov/dailymed/

drugInfo.cfm?setid=12b963dd-f189-11e3-ac10-0800200c9a66.

U.S. National Library of Medicine. Dailymed. Butorphanol

Tartarate – Butorphanol Tartarate Spray. Available from: https://www.

dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9c069ce5-ea674f42-afe4-30b01b4ce24d.

Meperidine HCl Tablet Demerol. Prescribing Information. SanofiAventis

Canada Inc. Available

from:

http://www.products.sanofi.ca/en/

demerol.pdf.

US. National Library of Medicine. Dailymed. Avinza - Morphine

Sulphate Capsule, Extended Release. Available from: https://www.

dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d06642a8-a26a4007-9ed6-812c4b87f1e8.

Published

01-07-2016

How to Cite

Mundhey, D. A., N. P. Sapkal, and A. S. Daud. “ADVANCES IN NONINVASIVE DRUG DELIVERY SYSTEMS OF OPIOIDS: FORMULATIONS AND CLINICAL PERSPECTIVE”. Asian Journal of Pharmaceutical and Clinical Research, vol. 9, no. 4, July 2016, pp. 341-7, https://mail.innovareacademics.in/journals/index.php/ajpcr/article/view/12325.

Issue

Section

Original Article(s)